UPPSALA, SWEDEN – LIDDS AB (publ) today announced the composition of the Nomination Committee for the Annual General Meeting 2023. The Nomination Committee shall, according to decided principles for the appointment of the Nomination Committee, consist of the Chairman of the Board and three representatives for the two largest shareholders.
The main task of the Nomination Committee is to submit proposals for Chairman of the Board and other members of the Board, remuneration for Board work, the election and remuneration of auditors. The Nomination Committee shall be composed of the Chairman of the Board and members appointed by the two largest shareholders in the company based on ownership of the Company as per the end of September 2022.
Accordingly, the following committee members have been appointed:
- Bengt-Åke Bengtsson, Chairman
- Olle Isaksson
- Bengt Viterius
- Jan Törnell, Chairman of LIDDS Board of Directors
The Nomination Committee’s proposals will be presented in the Notice to the Annual General Meeting 2023 and on the company web site, www.liddspharma.com. Shareholders desiring to submit comments or proposals to the nomination committee can send them via e-mail to email@example.com.